StockData

Cardiff Oncology vs Palisade Bio

CRDF and PALI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CRDF and PALI compare

Palisade Bio is the larger company, worth 2.7 times as much as Cardiff Oncology ($176M against $65.8M).

Palisade Bio keeps more of each dollar of sales as profit, with a net margin of −6388% compared with −7884% at Cardiff Oncology.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCRDFPALI
Size and price
Market cap$65.8M$176M
Share price$0.846$1.01
Change, 1 year−60.3%−52.8%
Change, 5 years−84.9%−99.9%
Beta (5Y)2.501.15
Employees31100K
StockData Score
Total score77
Valuation score01 (better)
Growth score1 (better)0
Performance score11
Health score55
Dividend score00
Valuation
P/S130× (better)352×
P/B2.5×1.4× (better)
Growth
Revenue growth (TTM)−7.0%–
Revenue growth, 5Y average10.1%–
Profitability
Operating margin−8320%−7070% (better)
Net margin−7884%−6388% (better)
Return on equity−94.1%−51.4% (better)
Financial health
Debt / equity0.000.00
Interest coverage–−4418.6×
Current ratio3.3024.26 (better)
Altman Z-score−16.2019.21 (better)
Piotroski F-score14 (better)
Dividends and buybacks
Buyback yield–−74.7%
Shareholder yield0.00% (better)−74.7%
Ownership
Held by institutions24.2%99.5%
Held by insiders4.9%4.7%
Insider net buying, 12 months$1.1M (better)−$124K
Short interest, % of float16.6%17.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.